"10.1371_journal.pone.0091119","plos one","2014-04-01T00:00:00Z","Daniel M Reed; Gabor Foldes; Timothy Gatheral; Koralia E Paschalaki; Zsuzsanna Lendvai; Zsolt Bagyura; Tamas Nemeth; Judit Skopal; Bela Merkely; Aurica G Telcian; Leila Gogsadze; Michael R Edwards; Peter J Gough; John Bertin; Sebastian L Johnston; Sian E Harding; Jane A Mitchell","Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Department of Cardiac Pharmacology, National Heart and Lung Institute, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, United Kingdom; Heart and Vascular Center, Semmelweis University, Budapest, Hungary; Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma and Centre for Respiratory Infection, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: DMR GF BM SEH JAM. Performed the experiments: DMR GF TG ZL ZB TN JS AGT LG MRE. Analyzed the data: DMR GF TG AGT MRE SLJ SEH JAM. Contributed reagents/materials/analysis tools: KEP PJG JB SLJ. Wrote the paper: DMR JAM.","The authors have read the journal's policy and have the following conflicts: PJG and JB are employees of GlaxoSmithKline, whose company provided the NOD1 (GSK1219217A) and RIP2 inhibitor (GSK2576214A) used in this study. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","04","Daniel M Reed","DMR",17,TRUE,5,10,8,2,TRUE,TRUE,FALSE,0,NA,FALSE
